New study aims to unravel muscle loss in advanced stomach cancer

NCT ID NCT06137508

Ongoing Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 125 patients with incurable gastroesophageal cancer to measure how much muscle they lose during chemotherapy. Researchers will collect blood, tissue samples, and track treatment side effects and survival. The goal is to better understand why muscle wasting happens and how it affects patients' outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help identify biological markers and risk factors for muscle wasting, pointing toward future treatments for cachexia.

What could go wrong

This is an observational study, not testing a treatment. It may not directly lead to new therapies, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRO-ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer neoplasm Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRO-ESOPHAGEAL CANCER

Contacts and locations

Show contact details

Locations

Rigshospitalet

Copenhagen, Denmark